Alendronate Sodium 11 Description (Ad670460 Alendronat Sodium Image 1)
Binosto
Product Images NDC 0178-0101
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Binosto (NDC 0178-0101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Mission Pharmacal Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Binosto 70mg Label (Ad670460 Blister Label)
NDC 117501070 is the product code for Binosto, a medication used to treat osteoporosis. It comes in an effervescent tablet form for oral solution, with each tablet containing 70 mg of alendronate sodium. This product is only available through a prescription. The last line “Pn maAE v"vl” is not readable and appears to be a scanning error.*
Binosto 70mg Carton 4 Tablets (Ad670460 Carton 04)
This is a description of a medication called Binosto, which is an effervescent tablet used to treat osteoporosis. The tablet contains alendronate sodium and is taken once a week. The dosage for the medication is 70mg. It's important to read the enclosed Medication Guide before use and keep out of reach and sight of children. It should be stored at 25°C with permissible excursions to 15°C-30°C. It's Rx only and manufactured for Mission Pharmacal Company in San Antonio, TX. The text also includes a dosage and the NDC number of the medicine.*
Figure 1 3 Yr Study (Ad670460 Figure 1 Placebo 3 Year Study)
Figure 2 Osteoporosis (Ad670460 Figure 2 Osteoporosis)
This is a diagram showing the increase in bone mineral density for postmenopausal women with osteoporosis taking Alendronate Sodium 10mg per day for three years. The bone mineral density increase is measured in percentage and compared to the placebo group. The bone density measurements are taken at various anatomical locations including the lumbar spine, femoral neck and trochanter.*
Figure 3 Osteoporosis (Ad670460 Figure 3 Osteoporosis)
This is a chart showing the effect of Alendronate Sodium 10 mg/day versus placebo on the bone mineral density (BMD) percent change from baseline in postmenopausal women with osteoporosis. The chart indicates data collected from both a US study and a multinational study over a time course of 36 months. The chart shows that Alendronate Sodium had a positive effect on BMD in the lumbar spine, resulting in an increase in percent change from baseline.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
